Arcus Biosciences Share Holder Equity 2017-2022 | RCUS

Arcus Biosciences share holder equity from 2017 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Arcus Biosciences Annual Share Holder Equity
(Millions of US $)
2021 $841
2020 $502
2019 $164
2018 $235
2017 $154
2016 $0
Arcus Biosciences Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $797
2021-12-31 $841
2021-09-30 $543
2021-06-30 $605
2021-03-31 $665
2020-12-31 $502
2020-09-30 $544
2020-06-30 $429
2020-03-31 $141
2019-12-31 $164
2019-09-30 $177
2019-06-30 $197
2019-03-31 $222
2018-12-31 $235
2018-09-30 $245
2018-06-30 $255
2018-03-31 $267
2017-12-31 $154
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.357B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00